B. Riley Adjusts Price Target on Novavax to $16
B. Riley analyst adjusted the price target for Novavax to $16 from $18 while maintaining a Buy rating.
Stocks · News reference
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
Novavax, Inc. has scheduled the release of its third quarter 2026 financial results for the morning of November 5, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
Novavax reported Q3 2026 loss of 19 cents per share, beating estimates, with revenues of $68 million exceeding consensus. The company raised 2026 revenue guidance to $385-$415 million, primarily driven by a $125 million Sanofi milestone. Despite operational improvements and cost reductions, shares fell 8.2% as investors focused on the one-time nature of the milestone and dependence on a potential 2029 U.S. vaccine launch for profitability.
B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
Novavax announced its Q3 2026 financial results, reporting $68.3 million in revenue and a narrowed net loss, while raising its full-year 2026 revenue guidance.
8-K filing — NOVAVAX INC (NVAX)
Filed: 2026-11-05 AccNo: 0001000694-26-000021 Size: 403 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
TD Cowen Raises Novavax Price Target to $11
TD Cowen has increased its price target for Novavax, Inc. from $9 to $11.